At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders.
In April 2016, we received FDA approval for NUPLAZID® (pimavanserin), the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including pimavanserin for dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and major depressive disorder and trofinetide for Rett syndrome.
Our vision is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drugs and drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.
Parkinson’s disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson’s disease. We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population.